Tweet
Antiviral Res. 2017 Oct 11. pii: S0166-3542(17)30147-X. doi: 10.1016/j.antiviral.2017.10.009. [Epub ahead of print]
Divalent copper complexes as influenza A M2 inhibitors.
Gordon NA1, McGuire KL1, Wallentine SK2, Mohl GA1, Lynch JD2, Harrison RG3, Busath DD4.
Author information
Abstract
New M2 blockers effective against the ubiquitous amantadine-resistant S31N M2 mutation in influenza A are needed. Six copper complexes, 2, 4, 6, 8, 9, and 10, were synthesized and found to block both wild type and S31N M2. Free Cu2+ also blocks M2 S31N but not S31N/H37A. The copper complexes do not block M2 H37A (either S31 or S31N). The complexes were effective against three influenza A strains in cell-culture assays, but less toxic to cells than CuCl2. For example 4, Cu(cyclooctylamineiminodiacetate), which was stable at pH > 4 in the buffers used, had an EC50 against A/Calif/07/2009 H1N1 of 0.7 ? 0.1 μM with a CC50 of 147 μM (therapeutic index, averaged over three strains, 67.8). In contrast, CuCl2 had an EC50 of 3.8 ? 0.9 μM and CC50 of 19 μM. Because M2 H37 is highly conserved, these complexes show promise for further testing as drugs against all strains of influenza A.
Copyright ? 2017. Published by Elsevier B.V.
KEYWORDS:
Electrophysiology; Medicinal metals; Plaque assay; Proton transport; Transfected oocytes; Tridentate chelation
PMID: 29032206 DOI: 10.1016/j.antiviral.2017.10.009
Divalent copper complexes as influenza A M2 inhibitors.
Gordon NA1, McGuire KL1, Wallentine SK2, Mohl GA1, Lynch JD2, Harrison RG3, Busath DD4.
Author information
Abstract
New M2 blockers effective against the ubiquitous amantadine-resistant S31N M2 mutation in influenza A are needed. Six copper complexes, 2, 4, 6, 8, 9, and 10, were synthesized and found to block both wild type and S31N M2. Free Cu2+ also blocks M2 S31N but not S31N/H37A. The copper complexes do not block M2 H37A (either S31 or S31N). The complexes were effective against three influenza A strains in cell-culture assays, but less toxic to cells than CuCl2. For example 4, Cu(cyclooctylamineiminodiacetate), which was stable at pH > 4 in the buffers used, had an EC50 against A/Calif/07/2009 H1N1 of 0.7 ? 0.1 μM with a CC50 of 147 μM (therapeutic index, averaged over three strains, 67.8). In contrast, CuCl2 had an EC50 of 3.8 ? 0.9 μM and CC50 of 19 μM. Because M2 H37 is highly conserved, these complexes show promise for further testing as drugs against all strains of influenza A.
Copyright ? 2017. Published by Elsevier B.V.
KEYWORDS:
Electrophysiology; Medicinal metals; Plaque assay; Proton transport; Transfected oocytes; Tridentate chelation
PMID: 29032206 DOI: 10.1016/j.antiviral.2017.10.009